Skip to content
Companies

Cynaptec Pharmaceuticals

Stable oral psilocin drug for psychiatric disorders

Raised to date

$6M

of $26M offered across 1 Form D filing

Still open
$20M
Investors
1
Last filed
Apr 17, 2025

About

Cynaptec Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurological and psychiatric disorders. Their primary emphasis lies in addressing significant unmet medical needs, particularly for conditions that currently lack effective treatments.

Cynaptec stands out by advancing a novel, stable analog of psilocin designed specifically for clinical use, aiming to provide effective solutions for chronic cluster headaches and potentially other psychiatric conditions.

Funding

  • EquityFiled Apr 17, 2025Form D
    $6M/ $26M

Product

Conjugated Psilocin™

Neurological Therapy

Conjugated Psilocin™ is a patented, oral, and stable analog of psilocin, which is the active metabolite of psilocybin. This compound has been engineered for enhanced stability and bioavailability, making it more suitable for clinical use compared to traditional psilocin formulations.

  • Oral administration
  • Increased stability
  • Improved bioavailability

Built for

Patients suffering from chronic cluster headaches

People on file